Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06630234
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-04
Brief Title:
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor GIST
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Master Protocol for the Multi-cohort Open-label Phase 12 Study of DCC-3009 in Participants with Gastrointestinal Stromal Tumor GIST
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Phase 12 master protocol study is to evaluate if DCC-3009 is safe tolerable and works effectively in the treatment of GIST The study will use a modular approach with each module being defined according to therapy DCC-3009 alone or DCC-3009 in combination with other anticancer therapies Each module will be conducted in 2 parts Part 1 Dose Escalation and Part 2 Dose Expansion Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None